Novavax | NVAX - Current Assets


Novavax reported $771.1M in Current Assets for its fiscal quarter ending in June of 2026.





Current Assets Change Date
Adma Biologics USD 528.2M 17.03M Jun/2026
Agenus USD 78.81M 16.47M Jun/2026
AstraZeneca USD 27.97B 1.65B Jun/2026
BioCryst Pharmaceuticals USD 484.68M 111.06M Jun/2026
Cassava Sciences USD 87.96M 9.74M Mar/2026
Geron USD 486.34M 12.19M Jun/2026
GlaxoSmithKline GBP 17.56B 202M Jun/2026
MannKind USD 245.71M 5.45M Jun/2026
Merck USD 36.68B 1.66B Jun/2026
Minerva Neurosciences USD 83.1M 70.08M Dec/2025
Moderna USD 5.82B 45M Jun/2026
Novartis USD 26.61B 3.85B Mar/2026
Novavax USD 771.1M 79.72M Jun/2026
Pfizer USD 41.36B 1.46B Jun/2026
Sanofi EUR 31.52B 1.36B Jun/2026
Sarepta Therapeutics USD 2.22B 86.05M Jun/2026
TG Therapeutics USD 1.15B 58.72M Jun/2026